Biogen

YTD

ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,605

Employees7,605

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,605

Employees7,605

BIIB Key Statistics

Market cap

20.40B

Market cap20.40B

Price-Earnings ratio

13.31

Price-Earnings ratio13.31

Dividend yield

—

Dividend yield—

Average volume

1.35M

Average volume1.35M

High today

$142.32

High today$142.32

Low today

$138.67

Low today$138.67

Open price

$140.41

Open price$140.41

Volume

656.75K

Volume656.75K

52 Week high

$206.76

52 Week high$206.76

52 Week low

$110.04

52 Week low$110.04

BIIB News

TipRanks 2h

Biogen’s Innovative Study on Litifilimab Delivery: Market Implications and Study Insights

Biogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Prem...

TipRanks 2h

Biogen’s Phase 3 Study on Felzartamab: A Potential Game-Changer for IgA Nephropathy

Biogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Prem...

TipRanks 2h

Biogen’s Litifilimab Study: A Potential Game-Changer for Lupus Treatment?

Biogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Prem...

Analyst ratings

49%

of 35 ratings

Buy

48.6%

Hold

48.6%

Sell

2.9%

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.